NCT06470282 - Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2025

Primary Completion Date

January 31, 2028

Study Completion Date

January 31, 2028

Conditions

Bladder CancerMuscle-Invasive Bladder CarcinomaStage II Bladder Cancer AJCC v8Stage IIIA Bladder Cancer AJCC v8

Interventions

DRUG

Enfortumab Vedotin

Given intravenously (IV)

BIOLOGICAL

Pembrolizumab

Given IV

RADIATION

Intensity Modulated Radiation Therapy (IMRT)

Undergo standard of care, IMRT

PROCEDURE

Transurethral Resection of Bladder Tumor

Undergo TURBT

PROCEDURE

Cystoscopy (CS)

Undergo cystoscopy

PROCEDURE

Computed Tomography (CT)

Undergo CT imaging

PROCEDURE

Magnetic Resonance Imaging (MRI)

Undergo MRI imaging

PROCEDURE

Positron Emission Tomography (PET)

Undergo PET Scan, may be combined with CT (PET/CT)

Trial Locations (1)

RECRUITING

University of California, San Francisco, San Francisco